Anya Ragnhildstveit

Anya Ragnhildstveit is a Clinical Research Scientist and PhD Candidate in Psychiatry at the University of Cambridge, where she is part of the Cambridge Psychedelic Research Group (CPRG). Her work focuses on the safety and therapeutic potential of dissociatives, empathogens, and classic psychedelics for severe mental illness.

She also serves as a psychedelic facilitator for industry-sponsored clinical trials at Inner Space Research. Anya is the Founder and CEO of Pneuma Science, an international research organisation exploring plant medicines and next-generation neuroplastogens to support mental health and human flourishing.

She has a particular research focus on 5-MeO-DMT, including publishing the first case study on its use for chronic PTSD and leading an observational study of 5-MeO-DMT-assisted Internal Family Systems (IFS) therapy. Alongside her research, Anya is active in psychedelic policy in the United States.

She first-authored a major technical report under Texas House Bill 1802 and, more recently, served as Lead Scientific Policy Advisor on Utah House Bill 390, supporting the development of a state-led clinical trial of 5-MeO-DMT-assisted therapy for veterans with treatment-resistant PTSD.